FOR IMMEDIATE RELEASE
EmpiraMed CEO Selected to NSBA Leadership Council
Greg Erman to Promote the Interests of Entrepreneurs to National Policymakers
Maynard, MA— January 14, 2019 — EmpiraMed, Inc., a leader in the field of patient engagement software, today announced that Greg Erman, President & CEO of EmpiraMed, has been named to the National Small Business Association (NSBA) Leadership Council. The NSBA is the nation’s oldest small-business advocacy organization and operates on a staunchly nonpartisan basis. Erman, a recognized leader in the Boston entrepreneur community, joins the NSBA Leadership Council alongside other small-business advocates from across the country as they work to promote the interests of small business to policymakers in Washington, D.C.
“I am proud to have Greg Erman as part of our Leadership Council,” stated NSBA President and CEO Todd McCracken. “He came to us highly recommended and I look forward to our coordinated efforts for years to come.”
“As a serial entrepreneur who has run 6 small businesses across multiple industries, I see daily the importance of being involved and active when it comes to laws and regulation,” stated Mr. Erman. “Joining NSBA’s Leadership Council will enable me to take our collective small-business message to the people that need to hear it most: Congress.” Erman joined the NSBA Leadership Council as part of his efforts to tackle the many critical issues facing growing technology companies like EmpiraMed, including data privacy regulations, health care costs, patent reform, regulatory restraint, access to capital, and how the Affordable Care Act will impact small business. The NSBA Leadership Council is focused on providing valuable networking between small-business advocates from across the country while ensuring small business a seat at the table as Congress and regulators take up key small-business proposals.
EmpiraMed’s technology was designed to be HIPAA compliant throughout, including encryption of all PHI, a fully configurable roles-based permission model, utilization of comprehensive logging and auditing of all Portal activities, and implementation of clinically rigorous patient consent workflows and methods. We have extended our system to meet GDPR requirements internationally.
New languages can be implemented rapidly using the rules engine and validated as needed. Languages are dynamically displayed according to the specific users’ preferences independent of localization of the Rewards Program by geographical region. In other words, local currencies and rules can be configured separately from local languages and local languages are automatically displayed based on user preferences. Different patient groups can have different user experiences within the same study or project with respect to language, currency, eGifts, redemption rules, and other study parameters.
For more on the NSBA Leadership Council, please visit http://www.nsba.biz
“I am proud to have Greg Erman as part of our Leadership Council,” stated NSBA President and CEO Todd McCracken. “He came to us highly recommended and I look forward to our coordinated efforts for years to come.”
“As a serial entrepreneur who has run 6 small businesses across multiple industries, I see daily the importance of being involved and active when it comes to laws and regulation,” stated Mr. Erman. “Joining NSBA’s Leadership Council will enable me to take our collective small-business message to the people that need to hear it most: Congress.” Erman joined the NSBA Leadership Council as part of his efforts to tackle the many critical issues facing growing technology companies like EmpiraMed, including data privacy regulations, health care costs, patent reform, regulatory restraint, access to capital, and how the Affordable Care Act will impact small business. The NSBA Leadership Council is focused on providing valuable networking between small-business advocates from across the country while ensuring small business a seat at the table as Congress and regulators take up key small-business proposals.
EmpiraMed’s technology was designed to be HIPAA compliant throughout, including encryption of all PHI, a fully configurable roles-based permission model, utilization of comprehensive logging and auditing of all Portal activities, and implementation of clinically rigorous patient consent workflows and methods. We have extended our system to meet GDPR requirements internationally.
New languages can be implemented rapidly using the rules engine and validated as needed. Languages are dynamically displayed according to the specific users’ preferences independent of localization of the Rewards Program by geographical region. In other words, local currencies and rules can be configured separately from local languages and local languages are automatically displayed based on user preferences. Different patient groups can have different user experiences within the same study or project with respect to language, currency, eGifts, redemption rules, and other study parameters.
About EmpiraMed
EmpiraMed has created a novel decentralized (or virtual) trial and registry patient-engagement software platform to generate Real World Evidence for the Life Science Industry. We have developed three products. The EmpiraMed™ PRO Portal™ Software Platform offers unsurpassed user “stickiness” to directly capture real world patient experience. Combining our fully automated study execution rules-engine, novel patient recruitment methods, and true mobile device independence, EmpiraMed delivers the most robust decentralized clinical study solution available. To that end, many of our prospective RWD studies are 100% site-less, from patient recruitment to execution, which few vendors can claim. Non-interventional studies typically suffer from poor patient participation, so our portal includes the ground-breaking Rewards Program which has improved patient engagement to more than 3X current industry standards. Consequently, our customers have seen dramatic increases in patient participation, compliance, wearable device utilization, and overall study success. In addition, our customers can now use this next-generation technology to file new indications for regulatory approval under the EmpiraMed™ DESTINI™ program, which is designed to reduce costs, expand patient access, and shorten time to market. To support Post Market Required Phase IV Studies, EmpiraMed has developed the PMR Portal™ patient medical record system to capture clinic routine care data while substantially reducing clinic burden and contracting. The PMR Portal directly addresses a common problem of poor clinic participation in regulatory agency mandated studies. We also offer an EDC and comprehensive forms management system for clinic study-specific data called the MED Portal™ platform. These three products have been used by R&D, Medical Affairs, HEOR, and Market Access to measure comparative effectiveness, demonstrate the value of treatments to prescribers, reduce reimbursement barriers, defend pricing, support REMS, implement longitudinal rare disease registries, develop Outcomes Based Contracting Programs that go beyond claims data, and offer Quality Improvement Intervention Projects to improve medication adherence. EmpiraMed’s software and services support all industry compliance requirements including HIPAA, GDPR, 21 CFR Part 11, and GCP. Studies can be internationalized using our automated, rules-based, localization system. Global leaders have used EmpiraMed’s technology in a wide variety of therapeutic areas since 2011, and our customers have included prominent biopharmaceutical manufacturers such as Merck Sharp & Dohme, Biogen, Janssen, Sanofi Genzyme, United Therapeutics, Teva, and Takeda. EmpiraMed also has contracts with leading Patient Advocacy Groups and Specialty Pharmacies to offer the Life Science Industry a unique and broad decentralized study solution.For more on the NSBA Leadership Council, please visit http://www.nsba.biz